Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 90 mg) |
Drug Class | Substance P/neurokinin 1 (NK1) receptor antagonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Latest News
Summary
- Varubi (rolapitant) is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- For Highly Emetogenic Chemotherapy (HEC), Rolapitant + Granisetron provided complete control of vomiting in 627 out of 1000 participants (RR 0.89, 95% CI 0.78 to 1.01). Compared to other drug combinations, its effectiveness was less than that of Fosnetupitant + Palonosetron (RR 1.15, 95% CI 0.97 to 1.37) and Aprepitant + Palonosetron (RR 1.07, 95% CI 1.98 to 1.18).
- For Moderately Emetogenic Chemotherapy (MEC), Rolapitant + Granisetron resulted in complete control of vomiting in 660 out of 1000 participants (RR 1.19, 95% CI 1.06 to 1.33). It was more effective than Aprepitant + Palonosetron (RR 1.29, 95% CI 1.00 to 1.66) but less effective than Fosaprepitant + Ondansetron (RR 0.90, 95% CI 0.66 to 1.22).
- In the context of Postoperative Nausea and Vomiting (PONV), Rolapitant showed high-certainty evidence for reducing vomiting within 24 hours postoperatively when compared with other NK₁ receptor antagonists, including Aprepitant (RR 0.26, 95% CI 0.18 to 0.38) and Granisetron (RR 0.45, 95% CI 0.38 to 0.54).
- For Chemotherapy-Induced Nausea and Vomiting (CINV), Highly Emetogenic Chemotherapy (HEC), Rolapitant + Granisetron: An estimated 20 out of 1000 participants experienced SAEs (RR 0.57, 95% CI 0.19 to 1.70; low certainty).
- For Chemotherapy-Induced Nausea and Vomiting (CINV), Moderately Emetogenic Chemotherapy (MEC), Rolapitant + Granisetron: Low-certainty evidence suggests 176 out of 1000 participants may experience SAEs (RR 1.15, 95% CI 0.88 to 1.50).
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Varubi (rolapitant) Prescribing Information. | 2020 | TerSera Therapeutics LLC., Deerfield, IL |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis. | 2021 | The Cochrane Database of Systematic Reviews |
Drugs for preventing postoperative nausea and vomiting in adults after general anesthesia: a network meta‐analysis. | 2020 | The Cochrane Database of Systematic Reviews |